Skip navigation
Image Alt

Detect recurrence earlier.

The first and most widely validated tumor-informed assay specifically designed for molecular residual disease (MRD) monitoring
Contact us for deeper insight into Signatera’s personalized, tumor-informed approach.


Is your cancer MRD test…

  • Predictive of treatment benefit
  • Pan-tumor
  • Quantitative
  • Personalized
  • Tumor-informed
  • Validated in thousands of patients

Exceptional Performance

  • 92% relapse sensitivity in the surveillance setting, based on multiple-peer reviewed studies1-4
  • Breadth of evidence from over 2000 patients, with consistent performance across multiple studies and tumor types5,6

Confident Decisions

  • Signatera validation showed persistent ctDNA clearance in 30% of patients who tested positive prior to treatment in a validation study with Stage II & III CRC patients1
  • Test performance has been evaluated for 3 critical decision points in early-stage CRC, compared to tumor-naive method1,6
    • 30 days post-surgery to inform adjuvant treatment decisions.
    • Single test post adjuvant treatment. 
    • Serial surveillance testing, to rule in / rule out recurrence

Reliable, quantitative ctDNA results

  • Easy-to-interpret report for serial monitoring
  • Optimized to monitor tumor response during treatment
  • Shows presence/absence of ctDNA and quantity in terms of copies/mL

Covered by Medicare

  • Benefits cover serial use of Signatera in patients with stage II or III colorectal cancer
  • Draft LCD proposes coverage of Signatera for immunotherapy response monitoring in all clinically validated solid tumor

    Enabling you to make more informed treatment decisions for improved patient care. Watch now to learn more.

    Dive deeper to learn more about Signatera

    References

    1 Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019.

    2 Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019;25(14):4255-4263.

    3 Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451.

    4 Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019;37(18):1547-1557.

    5 Signatera published data

    6 Parikh, A. et. al. Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma- only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay. ESMO 2020